This document reports on research that aimed to better characterize the contribution to drug-impaired driving in the U.S. associated with compounds that are not included as part of the standardized scope of testing set forth by the NSC-ADID recommendations.
This research report describes a project that aimed to comprehensively test blood samples collected and submitted for analysis to a reference laboratory for both Tier I and Tier II drugs and other emergent substances, including NPS in suspected Driving Under the Influence of Drugs (DUID) cases. The report presents the following information: the authors’ research questions; research design, methods, analytical and data analysis techniques, including sample acquisition and assessment; participants and other collaborating organizations; changes in approach to research and reasons for change; and outcomes for the five objectives. The authors’ objectives were: sample acquisition and analysis; method development and validation for identified analytes of interest; Drug Recognition Expert (DRE) evaluations; four-year assessment of DUID drug concentrations; and dissemination of research findings.
Downloads
Similar Publications
- The forensic mitochondrial DNA horizon: Laying the foundation to extend typing efforts to the full mitochondrial genome
- Questioning the prevalence and reliability of human mitochondrial DNA heteroplasmy from massively parallel sequencing data
- The Youth Protective Factors Study: A Strategy for Promoting Success Based on Risks, Strengths, and Development